Aims and objectives of this session
To discuss different surgical aspects of nephrectomy for advanced RCC.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

910 Renal tumor management in Scandinavia: A multi-institutional survey
By: Nisen H.¹, Jarvinen P.¹, Lund L.², Ljungberg B³, Kromann-Andersen B.⁴, Gudmundsson E.⁵, Sundqvist P.⁶, Fovaeus M.⁷, Nilsen F.⁸, Beisland C.⁹
Institutes: ¹HUCH Helsinki University Central Hospital, Dept. of Urology, Helsinki, Finland, ²Odense University Hospital, Dept. of Urology, Odense, Denmark, ³Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, ⁴Herlev University Hospital, Dept. of Urology, Copenhagen, Denmark, ⁵Landspitali, Dept. of Urology, Reykjavik, Iceland, ⁶Örebro University Hospital, Dept. of Urology, Örebro, Sweden, ⁷Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden, ⁸Akershus University Hospital, Dept. of Urology, Oslo, Norway, ⁹Haukeland University Hospital, Dept. of Urology, Bergen, Norway

911 Multicenter analysis of oncologic and renal functional outcomes of radical and partial nephrectomy in stage II renal cell carcinoma
By: Hamilton Z.¹, Correa A.², Larcher A.⁴, Khene Z.³, Fero K.¹, Han D.¹, Bloch A.¹, Field C.¹, Peyronnet B.³, Capitanio U.⁴, Montorsi F.⁴, Daneshmand S.⁶, Huang W.C.⁷, Martínez-Salamanca J.I.⁸, McKiernan J.M.⁹, Scherr D.S.¹⁰, Zigeuner R.¹¹, Libertino J.A.⁶
Institutes: ¹Moores Cancer Center, Dept. of Urology, La Jolla, United States of America, ²Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ³University of Rennes, Dept. of Urology, Rennes, France, ⁴San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

912 Partial versus radical nephrectomy in patients with renal cell carcinoma and renal or caval thrombus: Oncological and functional outcomes from an individual matched cohort analysis
By: Marra G.¹, Gontero P.¹, Brattoli M.¹, Filippini C.², Linares Espinos E.³, Capitanio U.⁴, Montorsi F.⁴, Daneshmand S.⁶, Huang W.C.⁷, Martínez-Salamanca J.I.⁸, McKiernan J.M.⁹, Scherr D.S.¹⁰, Zigeuner R.¹¹, Libertino J.A.⁶
Institutes: ¹San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy, ²San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy, ³Hospital Universitario Puerta De Hierro-Madrid, Dept. of Urology, Madrid, Spain, ⁴San Raffaele Hospital, Dept. of Urology, Milan, Italy, ⁵Lahey Clinic, Dept. of Urology, Burlington, United States of America, ⁶USC/Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ⁷University School of Medicine, Dept. of Urology, New York, United States of America, ⁸Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Dept. of Urology, Madrid, Spain, ⁹Columbia University College of Physicians and Surgeons, Dept. of Urology, New York, United States of America, ¹⁰Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, ¹¹Medical University of Graz, Dept. of Urology, Graz, Austria

913 Comparison of different surgical approaches for the management of renal cell carcinoma invading the renal vein
By: Hanna N., Ingham M., Seisen T., Chang S.
Institutes: Brigham and Women’s Hospital, Dept. of Urology, Boston, United States of America
914 Robot assisted radical nephrectomy and inferior vena cava thrombectomy: Surgical technique, perioperative and oncologic outcomes
By: Simone G.¹, Hatcher D.², Ferriero M.¹, Minisola F.¹, Misuraca L.¹, Tuderti G.¹, Guaglianone S.¹, De Castro Abreu A.L.², Aron M.², Desai M.², Gill I.S.², Gallucci M.¹
Institutes: Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²Keck School of Medicine, University of Southern California, Institute of Urology, Los Angeles, United States of America

915 Robotic versus open inferior Vena cava (IVC) tumor thrombectomy: The initial comparison
By: Chopra S., Loh-Doyle J., Cai J., Daneshman S., Djaladat H., Desai M., Gallucci M., Gill I.S.
Institutes: Usc Institute of Urology, Dept. of Urology, Los Angeles, United States of America

916 Comparison between laparoendoscopic single site nephrectomy and conventional laparoscopic nephrectomy: A randomized control single institution experience
Institutes: Cairo University, Dept. of Urology, Cairo, Egypt

917 Impact of intraoperative blood transfusions on survival after surgery for renal cell carcinoma
Institutes: RCCS Ospedale San Raffaele, Urological Research Institute, Unit of Urology, Division of Oncology, Milan, Italy

918 The efficacy of neoadjuvant targeted therapy in treatment of localized RCC
By: Voylenko O., Vitruk I., Stakhovskyi O., Kononenko O., Pikul M., Stakhovsky E.
Institutes: National Cancer Institute, Dept. of Plastic and Reconstructive Oncological Urology, Kiev, Ukraine

919 Clinical benefit of presurgical axitinib therapy in renal cell carcinoma patients with thrombus extending to inferior vena cava
Institutes: Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan

920 Phase II study of axitinib for downstaging cT2a to cT1 renal tumors for allowing partial nephrectomy (AXIPAN)
By: Lebacle C.¹, Bernhard J.C.², Bensalah K.³, Baumert H.⁴, Lang H.⁵, Jacqmin D.⁵, Duclos B.⁶, Ravaud A.⁷, Laguerre B.⁸, Albigeois L.⁹, Arnaud A.¹⁰, Escudier B.¹¹, Patard J.J.¹²
Institutes: Bicêtre University Hospital, Dept. of Urology, Le Kremlin-Bicêtre, France, ²Pellegrin Hospital, Dept. of Urology, Bordeaux, France, ³Pontchaillou University Hospital, Dept. of Urology, Rennes, France, ⁴Saint-Joseph Hospital, Dept. of Urology, Paris, France, ⁵Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Dept. of Urology, Strasbourg, France, ⁶Hôpitaux Universitaires de Strasbourg, Hôpital Hautepierre, Dept. of Oncology, Strasbourg, France, ⁷Saint-André Hospital, University Hospital, CHU Bordeaux, Dept. of Medical Oncology, Bordeaux, France, ⁸Eugène Marquis Center, Dept. of Oncology, Rennes, France, ⁹Gustave Roussy Université Paris-Saclay, Dept. of Medicine, Villejuif, France, ¹⁰Bicetre University Hospital, Dept. of Statistics, Le Kremlin-Bicêtre, France

921 Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer
By: Szabados B.¹, Gomez De Liano Lista A.¹, Wimalasingham A.¹, De Bruijn R.², Haanen J.³, Blank C.³, Hall P.⁴, Staehler M.⁵, Chowdhury S.⁵, Hopkins T.⁶, Powles T.⁶, Bex A.²
Institutes: ¹Barts Health NHS Trust St Bartholomew’s Hospital, Dept. of Oncology, London, United Kingdom, ²The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ³The Netherlands Cancer Institute, Dept. of Oncology, Amsterdam, The Netherlands, ⁴Barts Health NHS Trust St Bartholomew’s Hospital, Dept. of Oncology, London, United Kingdom, ⁵Guy’s, King’s and St Thomas’ Hospitals, Dept. of Oncology, London, United Kingdom, ⁶University Hospital Munich-
S-TRAC adjuvant sunitinib phase 3 trial in patients with high risk renal cell carcinoma: Subgroups analyses by risk factors


Institutes: 1University Hospital of Munich, Dept. of Urology, Munich, Germany, 2Bicêtre Hospital, Paris-Saclay University, Dept. of Urology, Le Kremlin Bicêtre, France, 3Ronald Reagan UCLA Medical Center, Dept. of Urology, Los Angeles, Ca, United States of America, 4Bordeaux University Hospital, Dept. of Medical Oncology, Bordeaux, France, 5Memorial Sloan Kettering Cancer Center, Dept. of Oncology, New York, United States of America, 6University of Surrey, Dept. of Clinical and Experimental Medicine, Surrey, United Kingdom, 7Duke Cancer Center, Dept. of Oncology, Durham, United States of America, 8Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, 9Institut Gustave Roussy, Dept. of Medical Oncology, Villejuif, France, 10Aarhus University Hospital, Dept. of Oncology, Aarhus, Denmark, 11Charité Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, 12Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Dept. of Oncology and Urology, Naples, Italy, 13Centre Eugene Marquis, Dept. of Medical Oncology, Rennes, France, 14Klinika Onkologii Oddzial Chemioterapii, Dept. of Oncology, Poznan, Poland, 15Slovak Medical University In Bratislava, Dept. of Urology, Bratislava, Slovakia, 16Pfizer S.r.L, Dept. of Oncology, Milan, Italy, 17Pfizer Inc, Dept. of Oncology, La Jolla, United States of America, 18Pfizer Inc, Dept. of Oncology, New York, United States of America, 19Spire Roding Hospital, Dept. of Urology, London, United Kingdom

Summary

M.C. Mir Maresma, Cleveland (US)